Validation of the Atopic Dermatitis Control Tool (ADCT©) using a longitudinal survey of biologic-treated patients with atopic dermatitis
Eric L. Simpson(Oregon Health & Science University), David M. Pariser(Eastern Virginia Medical School), Mark Boguniewicz(University of Colorado Denver), Usha G. Mallya, Matt Reaney(Sanofi (United Kingdom)), T. Michelle Brown(RTI Health Solutions), Min Yang(Analysis Group (United States)), Lauren Nelson(RTI Health Solutions), Isabelle Guillemin, Abhijit Gadkari(Regeneron (United States)), Puneet Mahajan(Research Triangle Park Foundation), Laurent Eckert(Sanofi (France))
Cited by 92
Related Papers
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2.1k
Cytokine modulation of atopic dermatitis filaggrin skin expression
|Journal of Allergy and Clinical Immunology|2007|1.1k
Tight junction defects in patients with atopic dermatitis
|Journal of Allergy and Clinical Immunology|2010|741
Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: An international consensus
|Journal of the American Academy of Dermatology|2006|654